Introduction
Vernal Keratoconjunctivitis (VKC) is a chronic, bilateral allergic inflammation of the conjunctiva. The disease is seasonal, recurrent & commonly seen among young boys. The management of VKC includes correct diagnosis, prognostic evaluation and proper therapy. There are many therapeutic options and the selection of the drug depends on the severity of the disease. However at present no drug is available to achieve the ultimate goal of therapy, meaning the complete resolution of the disease & prevention of recurrence. Most commonly used drug is topical steroid which controls effectively the acute phase of the disease but may lead to complications of glaucoma & cataract on prolong use (8, 9). Second line drugs are topical antihistamines, mast cell stabilizers & non steroidal anti-inflammatory drugs (NSAID). Topical cyclosporine 2% is effective in chronic cases but about 6% of patients develop complications of cataract, corneal damage or glaucoma.
Montelukast which is a leukotriene receptor 1 antagonist has the potential to reduce the symptoms of VKC as it has been found that biological activity of leukotriene on conjunctiva produces a similar picture as that of VKC (10).
AIM:
To study the efficacy of oral Montelukast in reducing the symptoms & recurrence in cases of VKC.
MATERIALS & METHODS:
This was a prospective, randomized, control clinical trial. 58 patients of VKC patients attending the outpatient department of Ophthalmology at Muzaffarnagar Medical College from March 2014 to August 2014 were enrolled for the study. The diagnosis of VKC was clinical, based on the symptoms & signs. Exclusion criteria were the patients already on treatment from our department or elsewhere. An informed consent was taken from parents of all the patients. The age & sex distribution was according to Table 1 . 
OBSERVATIONS:
58 patients who were clinically diagnosed as having VKC on the basis of signs & symptoms were distributed according to the grade of severity Table 2 . At the conclusion of the study (at 6 weeks of treatment), all the 10 patients of Group A & 6 patients of Group B of Grade 1 severity were found symptom & sign free. 6 patients of Group B of grade 2 severity showed improvement & were so included in Grade 1 severity. Hence after 6 weeks it was observed that all the patients of Group A who were on both topical olopatadine & oral montelukast became totally symptom free. However 10 patients of Group B who were on topical olopatadine alone were still found to have some symptoms & signs of VKC. (Table 6 ) This study has its limitations because of a small sample size & short duration of the study. A long term study is needed to evaluate the effect a long lasting efficacy of the drug as well as its role in prevention of the recurrence. However we feel that despite its limitations, the drug appears to be promising. It should be viewed in context that no such study is reported so far at least from India, to the best of our knowledge.
CONCLUSION:
After the improved knowledge of the pathogenesis of VKC, the use of leukotriene receptor antagonist (Montelukast) as an adjunct is justified. Montelukast 5 mg orally at bed time along with topical olopatadine twice a day showed much more improvement than topical olopatadine used alone in VKC. Combination treatment was more effective & had significant & persistent reduction in signs & symptoms even after the discontinuation of the oral treatment. It was also observed that the effect was long lasting with lesser recurrence.
There were no significant side effects of the oral medication. It is a safe drug when used in 5 mg daily dose in patients less than 15 years of age. However a double masked placebo controlled study is required to confirm the potential of this new treatment modality in vernal kerato conjunctivitis.
